Volm M, Kaufmann M, Mattern J, Wayss K
Schweiz Med Wochenschr. 1975 Jan 18;105(3):74-82.
The following cytostatic agents were tested for activity in vivo and in vitro inWalker carcinosarcoma 256 of the rat: cyclophosphamide, triaziquon, 5-fluorouracil, methotrexate, adriamycin, dactinomycin, daunorubicin, hydroxyurea, procarbazin and vincritine. With the exception of vincristine, the results of therapy in vivo could be predicted by using a rapid in vitro test system. This involved, for cyclosphosphamide, triaziquon, adriamycin, and daunorubicin, the measurement of 3H-uridine or 3H-thymidine incorporation. The activities of methotrexate and 5-fluorouracil could be determined from 3H-deoxyuridine incorporation and that of dactinomycin from 3H-uridine incorporation. The results of short-term tests (uring adriamycin, daunorubicin, and dactinomycin) in roughly 100 human tumors were compared with data in the literature on therapy with the same cytostatic agents. Good agreement was found between the results of in vitro tests and the literature data on clinical therapy.
对以下细胞抑制剂在大鼠的Walker癌肉瘤256中进行了体内和体外活性测试：环磷酰胺、三嗪醌、5-氟尿嘧啶、甲氨蝶呤、阿霉素、放线菌素D、柔红霉素、羟基脲、丙卡巴肼和长春新碱。除长春新碱外，使用快速体外测试系统可以预测体内治疗结果。对于环磷酰胺、三嗪醌、阿霉素和柔红霉素，这涉及测量3H-尿苷或3H-胸苷掺入。甲氨蝶呤和5-氟尿嘧啶的活性可以通过3H-脱氧尿苷掺入来确定，放线菌素D的活性可以通过3H-尿苷掺入来确定。将阿霉素、柔红霉素和放线菌素D的短期测试结果在大约100个人类肿瘤中的情况与文献中关于相同细胞抑制剂治疗的数据进行了比较。体外测试结果与临床治疗的文献数据之间发现了良好的一致性。
